VOR Vor Biopharma Inc.

16.68
+0.82  (+5%)
Previous Close 15.86
Open 15.94
52 Week Low 11.78
52 Week High 63.62
Market Cap $619,571,378
Shares 37,144,567
Float 14,880,424
Enterprise Value $362,002,386
Volume 102,008
Av. Daily Volume 153,355
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
VOR33
Acute myeloid leukemia (AML)
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
VCAR33
Acute myeloid leukemia (AML)
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the presentation of data from its novel engineered hematopoietic stem cell (eHSC) platform at the ESGCT Annual Congress, taking place virtually October 19-22, 2021.

    "The preclinical data being presented at ESGCT formed the core foundation and rationale for our recently initiated Phase 1/2a clinical trial of VOR33 in patients with acute myeloid leukemia," said Tirtha Chakraborty, Ph.D., Chief Scientific Officer at Vor. "We believe our unique cell engineering approach, which aims to make healthy cells invisible to targeted therapies in a post-transplant setting, has the potential to change the…

    CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the presentation of data from its novel engineered hematopoietic stem cell (eHSC) platform at the ESGCT Annual Congress, taking place virtually October 19-22, 2021.

    "The preclinical data being presented at ESGCT formed the core foundation and rationale for our recently initiated Phase 1/2a clinical trial of VOR33 in patients with acute myeloid leukemia," said Tirtha Chakraborty, Ph.D., Chief Scientific Officer at Vor. "We believe our unique cell engineering approach, which aims to make healthy cells invisible to targeted therapies in a post-transplant setting, has the potential to change the current standard of care for patients with blood cancers."

    ESGCT Annual Congress Presentations

    Oral Presentation



    Title: Pre-clinical evaluation, including genomic off-target analysis, of VOR33: a clinic-ready CRISPR/Cas9 engineered hematopoietic stem cell transplant for the treatment of acute myeloid leukemia

    Presenter: John Lydeard, Ph.D., Program Lead for VOR33 and Head of Target Discovery, Vor

    Oral Presentation Number: OR36

    Session Title: Session 4c: Hematopoietic & bleeding disorders I

    Session Date/Time: Thursday, October 21, 2021, 9:00-11:00am (CEST)

    Virtual Poster Presentation



    Title: In depth assessment of off-target editing by CRISPR/Cas9 in VOR33, an engineered hematopoietic stem cell transplant for the treatment of acute myeloid leukemia

    Presenter: Dane Hazelbaker, Ph.D., Group Leader of Molecular and Genomic Assays, Vor

    Poster Number: P112

    Presentation Date/Time: Virtual poster presentations are available to registered participants beginning at 8:00am CEST on the first day of the congress, October 19, 2021.

    The slides and poster from these presentations are available on the Vor Biopharma corporate website at https://ir.vorbio.com/news-and-events/events-and-presentations.

    About Vor Biopharma

    Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Biopharma's statements regarding the potential efficacy of its cell engineering approach. Vor Biopharma may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Biopharma's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the impact of the COVID-19 pandemic on Vor Biopharma's business, including its preclinical studies and clinical trials and availability of funding sufficient for Vor Biopharma's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Biopharma's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Biopharma expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

    Contacts:

    Media:

    Sarah Spencer

    +1 857-242-6076

    sspencer@vorbio.com

    Investors:

    Chris Brinzey

    ICR Westwicke

    +1 339-970-2843

    chris.brinzey@westwicke.com



    Primary Logo

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vor's Senior Vice President of Program and Alliance Management. Dr. Schmelmer has more than 25 years of experience leading the development of novel therapies for cancer, autoimmune disorders and infectious diseases at leading biopharmaceutical companies.

    Dr. Schmelmer will oversee the management of Vor's key programs, leading cross-functional teams across the organization and working with external collaborators to advance the company's mission to change the standard of care for patients with blood cancer by engineering hematopoietic stem cells to…

    CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vor's Senior Vice President of Program and Alliance Management. Dr. Schmelmer has more than 25 years of experience leading the development of novel therapies for cancer, autoimmune disorders and infectious diseases at leading biopharmaceutical companies.

    Dr. Schmelmer will oversee the management of Vor's key programs, leading cross-functional teams across the organization and working with external collaborators to advance the company's mission to change the standard of care for patients with blood cancer by engineering hematopoietic stem cells to enable targeted therapies post-transplant.



    "We are excited to welcome Veit to our team during this critical period at Vor as enrollment of our Phase 1/2a clinical trial of VOR33 continues. His deep expertise overseeing the development of novel therapies, particularly his work with hematopoietic stem cells, will prove invaluable to us as our therapeutic candidates progress through clinical development. Most importantly, his unwavering dedication to patients makes him an ideal fit for our company culture and leadership team," said Robert Ang, MBBS, MBA, President and Chief Executive Officer at Vor.



    "I joined Vor because I believe in the company's vision: to cure blood cancers through cell and genome engineering," said Dr. Schmelmer. "I am thrilled to join this impressive team of industry leaders who share my commitment to patients. I look forward to collaborating with teams across the organization and with our key partners to make our vision a reality through further development of our novel engineered hematopoietic stem cell (eHSC) platform."



    Prior to joining Vor, Dr. Schmelmer was most recently Vice President, Project Lead at Magenta Therapeutics, where he oversaw global program development for MGTA-145, a novel biologic therapeutic candidate currently in Phase 2 clinical trials designed to mobilize hematopoietic stem cells prior to bone marrow transplant. He previously served as Vice President of Portfolio Strategy at Mersana Therapeutics with responsibility for project leadership, alliance management and portfolio strategy. Dr. Schmelmer also served as Global Project Leader for Takeda Pharmaceuticals International (formerly Millennium Pharmaceuticals) where he was directly responsible for the company's global asset strategy for new pipeline projects, overseeing programs in oncology from late-stage discovery, pre-clinical development and approval. Notably, Dr. Schmelmer directed the global development of Entyvio® through Phase 2 and 3 clinical development, MAA/BLA review, global approvals and launch. Dr. Schmelmer began his career at Boehringer Ingelheim where he held positions of increasing seniority, becoming the Head of the Department of Chemistry, Manufacturing and Control for its Japanese subsidiary. Dr. Schmelmer is a board-certified pharmacist in Germany and he obtained a Ph.D. from Heidelberg University with a focus in formulation development.

    About Vor Biopharma

    Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "continue," "could," "estimate," "expect," "intend," "may," "mission," "plan," "potential," "project," "should," "target," "vision," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Vor Biopharma may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Biopharma's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the impact of the COVID-19 pandemic on Vor Biopharma's business, including its preclinical studies and clinical trials and availability of funding sufficient for Vor Biopharma's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Biopharma's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Biopharma expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

    Contacts:

    Media:

    Sarah Spencer

    +1 857-242-6076

    sspencer@vorbio.com

    Investors:

    Chris Brinzey

    Westwicke, an ICR Company

    +1 339-970-2843

    chris.brinzey@westwicke.com



    Primary Logo

    View Full Article Hide Full Article
  3. PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (NASDAQ:VOR) ("Vor") announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to VOR33, Vor's lead engineered hematopoietic stem cell ("eHSC") therapeutic candidate for the treatment of acute myeloid leukemia ("AML").

    VOR33, the lead product candidate from Vor's novel scientific platform, consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33. Once infused, VOR33 is designed to protect patients' healthy cells from anti-CD33 therapies, such as VCAR33 or Mylotarg™ (gemtuzumab…

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (NASDAQ:VOR) ("Vor") announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to VOR33, Vor's lead engineered hematopoietic stem cell ("eHSC") therapeutic candidate for the treatment of acute myeloid leukemia ("AML").

    VOR33, the lead product candidate from Vor's novel scientific platform, consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33. Once infused, VOR33 is designed to protect patients' healthy cells from anti-CD33 therapies, such as VCAR33 or Mylotarg™ (gemtuzumab ozogamicin). VOR33 is intended to replace standard of care transplants for AML patients who are at high risk of relapse and has the potential to seamlessly integrate into current transplant settings.

    Vor is actively enrolling in its Phase 1/2a clinical trial for AML patients who currently have limited treatment options. Vor remains on track to report VOR33's initial clinical data in the first half of 2022. Vor is also currently exploring the use of its genome engineered hematopoietic stem cell platform in combination with multiple therapeutic modalities.

    The full text of the announcement from Vor is as follows:

    VOR33 Granted U.S. FDA Fast Track Designation for AML

    CAMBRIDGE, Mass., Sept. 09, 2021 – Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Company's lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).

    VOR33 consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33. Once infused, VOR33 is designed to protect patients' healthy cells from anti-CD33 therapies, such as VCAR33 or Mylotarg™ (gemtuzumab ozogamicin). VOR33 is intended to replace standard of care transplants for AML patients who are at high risk of relapse and has the potential to seamlessly integrate into current transplant settings.

    "Receiving Fast Track designation is an important milestone for Vor, which signals the FDA's recognition of the serious and life-threatening medical condition of patients facing acute myeloid leukemia and the potential of VOR33 to address this unmet medical need," said Robert Pietrusko, PharmD, Vor's Chief Regulatory and Quality Officer. "We will continue to work closely with the FDA to expedite the development of VOR33, which is now actively enrolling in its Phase 1/2a clinical trial for AML patients who currently have limited treatment options. We continue to remain on-track to report VOR33's initial clinical data in the first half of 2022."

    VOR33 is the lead product candidate of Vor's novel scientific platform, which has the mission to create next-generation, treatment-resistant transplants that unlock the potential of targeted cancer therapies by leveraging advances in cell therapy and gene editing. Vor is currently exploring the use of its genome engineered hematopoietic stem cell platform in combination with multiple therapeutic modalities.

    Fast Track designation is intended to facilitate development and expedite review of products designed to treat serious and life-threatening conditions with unmet medical needs. The designation is granted upon the FDA's review of data that demonstrate this potential, along with a product development program that is adequately designed to address the unmet medical need. Therapeutic candidates receiving Fast Track designation may be eligible for priority review and accelerated approval if certain conditions are met.

    About Vor Biopharma

    Vor Biopharma is a clinical-stage cell and genome engineering company that aims to transform the lives of cancer patients by pioneering an engineered hematopoietic stem cell (eHSC) therapeutic platform that unlocks the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancer cells while sparing healthy cells.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include the Company's statements regarding the potential efficacy of VOR33, potential benefits VOR33 may receive in connection with its Fast Track designation and reporting initial clinical data from the VOR33 Phase 1/2a clinical trial in the first half of 2022. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the impact of the COVID-19 pandemic on the Company's business, including its preclinical studies and clinical trials and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent annual or quarterly report and in other reports the Company has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

    About PureTech Health

    PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 25 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Half Year Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

    For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains statements that are or may be forward-looking statements, including statements that relate to expectations regarding the potential efficacy of VOR33, potential benefits VOR33 may receive in connection with its Fast Track designation and the anticipated timing of the initial clinical data from the VOR33 Phase 1/2a clinical trial in the first half of 2022, and Vor's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the Company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

    View Full Article Hide Full Article
  4. CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Company's lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).

    VOR33 consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33. Once infused, VOR33 is designed to protect patients' healthy cells from anti-CD33 therapies, such as VCAR33 or Mylotarg™ (gemtuzumab ozogamicin). VOR33 is intended to replace standard of care transplants for AML patients who are at high risk of relapse…

    CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Company's lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).

    VOR33 consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33. Once infused, VOR33 is designed to protect patients' healthy cells from anti-CD33 therapies, such as VCAR33 or Mylotarg™ (gemtuzumab ozogamicin). VOR33 is intended to replace standard of care transplants for AML patients who are at high risk of relapse and has the potential to seamlessly integrate into current transplant settings.

    "Receiving Fast Track designation is an important milestone for Vor, which signals the FDA's recognition of the serious and life-threatening medical condition of patients facing acute myeloid leukemia and the potential of VOR33 to address this unmet medical need," said Robert Pietrusko, PharmD, Vor's Chief Regulatory and Quality Officer. "We will continue to work closely with the FDA to expedite the development of VOR33, which is now actively enrolling in its Phase 1/2a clinical trial for AML patients who currently have limited treatment options. We continue to remain on-track to report VOR33's initial clinical data in the first half of 2022."

    VOR33 is the lead product candidate of Vor's novel scientific platform, which has the mission to create next-generation, treatment-resistant transplants that unlock the potential of targeted cancer therapies by leveraging advances in cell therapy and gene editing. Vor is currently exploring the use of its genome engineered hematopoietic stem cell platform in combination with multiple therapeutic modalities.



    Fast Track designation is intended to facilitate development and expedite review of products designed to treat serious and life-threatening conditions with unmet medical needs. The designation is granted upon the FDA's review of data that demonstrate this potential, along with a product development program that is adequately designed to address the unmet medical need. Therapeutic candidates receiving Fast Track designation may be eligible for priority review and accelerated approval if certain conditions are met.

    About Vor Biopharma

    Vor Biopharma is a clinical-stage cell and genome engineering company that aims to transform the lives of cancer patients by pioneering an engineered hematopoietic stem cell (eHSC) therapeutic platform that unlocks the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancer cells while sparing healthy cells.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include the Company's statements regarding the potential efficacy of VOR33, potential benefits VOR33 may receive in connection with its Fast Track designation and reporting initial clinical data from the VOR33 Phase 1/2a clinical trial in the first half of 2022. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the impact of the COVID-19 pandemic on the Company's business, including its preclinical studies and clinical trials and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent annual or quarterly report and in other reports the Company has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

    Contacts:

    Investors:

    Chris Brinzey

    Westwicke, an ICR Company

    +1 339-970-2843

    chris.brinzey@westwicke.com

    Media:

    Rebecca Spalding

    Ten Bridge Communications

    +1 646-509-3831

    rebecca@tenbridgecommunications.com 



    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a cell and genome engineering company, today announced that the Company will be participating in three upcoming virtual investor conferences:

    Morgan Stanley Virtual 19th Annual Global Healthcare Conference
    Fireside Chat Date: Friday, September 10, 2021
    Time: 2:00 PM ET

    H.C. Wainwright 23rd Annual Global Investment Conference
    Date: Monday, September 13th through Wednesday, September 15th, 2021

    Oppenheimer's Virtual Fall Healthcare Life Sciences & MedTech Summit
    Presentation Date: Wednesday, September 22, 2021
    Time: 3:45 PM ET

    The fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference and presentation at the Oppenheimer Virtual…

    CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a cell and genome engineering company, today announced that the Company will be participating in three upcoming virtual investor conferences:

    Morgan Stanley Virtual 19th Annual Global Healthcare Conference

    Fireside Chat Date: Friday, September 10, 2021

    Time: 2:00 PM ET

    H.C. Wainwright 23rd Annual Global Investment Conference

    Date: Monday, September 13th through Wednesday, September 15th, 2021

    Oppenheimer's Virtual Fall Healthcare Life Sciences & MedTech Summit

    Presentation Date: Wednesday, September 22, 2021

    Time: 3:45 PM ET

    The fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference and presentation at the Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit will be webcast live. A pre-recorded webcast of the presentation at the H.C. Wainwright 23rd Annual Global Investment Conference will be made available on Monday, September 13, 2021, at 7:00 AM ET. All of the webcasts can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay of each webcast will also be available.

    About Vor Biopharma

    Vor Biopharma is a cell and genome engineering company that aims to transform the lives of cancer patients by pioneering an engineered hematopoietic stem cell (eHSC) therapeutic platform that unlocks the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancer cells while sparing healthy cells.

    Contacts:



    Investors:

    Chris Brinzey

    Westwicke, an ICR Company

    +1 339-970-2843

    chris.brinzey@westwicke.com

    Media:

    Rebecca Spalding

    Ten Bridge Communications

    +1 646-509-3831

    rebecca@tenbridgecommunications.com



    Primary Logo

    View Full Article Hide Full Article
View All Vor Biopharma Inc. News